Showing 49 to 60 of 70 results
US Pharmaceutical Companies Protest Australia's Affordable Medicine Scheme
Australia's Pharmaceutical Benefits Scheme (PBS) subsidizes medicine costs, with the government negotiating lower prices, resulting in a maximum cost of $31.60 per script (decreasing to $25 next year) for Australians. The system is under threat from US pharmaceutical companies, who argue it limits t...
US Pharmaceutical Companies Protest Australia's Affordable Medicine Scheme
Australia's Pharmaceutical Benefits Scheme (PBS) subsidizes medicine costs, with the government negotiating lower prices, resulting in a maximum cost of $31.60 per script (decreasing to $25 next year) for Australians. The system is under threat from US pharmaceutical companies, who argue it limits t...
Progress
52% Bias Score
Generic Ozempic Approaching Canada: Potential Cost Savings and Market Disruption
Generic versions of the blockbuster weight-loss drug Ozempic could be available in Canada as early as next year, potentially slashing costs by 65 percent and increasing patient access, based on applications from at least four companies; however, the impact on public drug plans remains unclear.
Generic Ozempic Approaching Canada: Potential Cost Savings and Market Disruption
Generic versions of the blockbuster weight-loss drug Ozempic could be available in Canada as early as next year, potentially slashing costs by 65 percent and increasing patient access, based on applications from at least four companies; however, the impact on public drug plans remains unclear.
Progress
44% Bias Score
Dutch Insurers Limit Coverage of Two Breast Cancer Drugs
Dutch health insurers ended full coverage for two expensive breast cancer drugs (ribociclib and abemaciclib), impacting 2,000 women, due to high costs and a price negotiation failure with drug manufacturers, despite oncologists' concerns about differing drug effectiveness and side effects.
Dutch Insurers Limit Coverage of Two Breast Cancer Drugs
Dutch health insurers ended full coverage for two expensive breast cancer drugs (ribociclib and abemaciclib), impacting 2,000 women, due to high costs and a price negotiation failure with drug manufacturers, despite oncologists' concerns about differing drug effectiveness and side effects.
Progress
48% Bias Score
Pfizer Q4 Earnings Beat Expectations Amidst Covid Revenue Decline and Cost-Cutting Success
Pfizer's Q4 2024 earnings beat analysts' estimates, reporting adjusted EPS of $0.63 and revenue of $17.76 billion, exceeding expectations due to strong Covid product sales and cost reductions; however, future challenges remain due to the Inflation Reduction Act's impact and market competition.
Pfizer Q4 Earnings Beat Expectations Amidst Covid Revenue Decline and Cost-Cutting Success
Pfizer's Q4 2024 earnings beat analysts' estimates, reporting adjusted EPS of $0.63 and revenue of $17.76 billion, exceeding expectations due to strong Covid product sales and cost reductions; however, future challenges remain due to the Inflation Reduction Act's impact and market competition.
Progress
40% Bias Score
£60,000 Alzheimer's Drug Faces Criticism Over Limited Benefits and High Risks
A new £60,000-a-year Alzheimer's drug, Donanemab, offered privately in London, is criticized for minimal benefits and risks like brain swelling and bleeding, despite UK regulator approval; NHS rejected it due to cost-ineffectiveness.
£60,000 Alzheimer's Drug Faces Criticism Over Limited Benefits and High Risks
A new £60,000-a-year Alzheimer's drug, Donanemab, offered privately in London, is criticized for minimal benefits and risks like brain swelling and bleeding, despite UK regulator approval; NHS rejected it due to cost-ineffectiveness.
Progress
60% Bias Score
FTC Accuses PBMs of \$8.7 Billion in Price Gouging
The FTC released a report accusing the three largest Pharmacy Benefit Managers (PBMs)—OptumRx, Express Scripts, and CVS Caremark—of marking up specialty generic drug prices by over \$7.3 billion from 2017-2022, and an additional \$1.4 billion through spread pricing, ultimately increasing patient cos...
FTC Accuses PBMs of \$8.7 Billion in Price Gouging
The FTC released a report accusing the three largest Pharmacy Benefit Managers (PBMs)—OptumRx, Express Scripts, and CVS Caremark—of marking up specialty generic drug prices by over \$7.3 billion from 2017-2022, and an additional \$1.4 billion through spread pricing, ultimately increasing patient cos...
Progress
24% Bias Score
High Cost of GLP-1 Weight Loss Drugs Limits Cost-Effectiveness
A JAMA Health Forum study found that despite improved health outcomes, GLP-1 weight loss medications like Wegovy and Zepbound are not currently cost-effective due to high net prices, patient non-persistence, and insurer churn; price reductions of 30% for tirzepatide and 82% for semaglutide are neede...
High Cost of GLP-1 Weight Loss Drugs Limits Cost-Effectiveness
A JAMA Health Forum study found that despite improved health outcomes, GLP-1 weight loss medications like Wegovy and Zepbound are not currently cost-effective due to high net prices, patient non-persistence, and insurer churn; price reductions of 30% for tirzepatide and 82% for semaglutide are neede...
Progress
56% Bias Score
Trump's Pharmaceutical Tariffs Threaten Global Drug Supply
President Trump's proposed 25 percent tariffs on European pharmaceutical imports threaten to raise drug prices in the U.S. and disrupt global supply chains, prompting concerns about patient access to essential medicines and potential retaliatory measures from the EU.
Trump's Pharmaceutical Tariffs Threaten Global Drug Supply
President Trump's proposed 25 percent tariffs on European pharmaceutical imports threaten to raise drug prices in the U.S. and disrupt global supply chains, prompting concerns about patient access to essential medicines and potential retaliatory measures from the EU.
Progress
40% Bias Score
IRA's Drug Price Controls Threaten Generic Drug Market
The Inflation Reduction Act's (IRA) price negotiation provision for prescription drugs, while intending to lower costs, risks undermining the generic drug market by reducing profit incentives for generic manufacturers, potentially limiting patient access to affordable medications and decreasing inno...
IRA's Drug Price Controls Threaten Generic Drug Market
The Inflation Reduction Act's (IRA) price negotiation provision for prescription drugs, while intending to lower costs, risks undermining the generic drug market by reducing profit incentives for generic manufacturers, potentially limiting patient access to affordable medications and decreasing inno...
Progress
60% Bias Score
France Secures Continued Wegovy Access Pending Price Negotiation
Novo Nordisk will continue providing free Wegovy to 3,000 French patients until at least December 2025 while negotiating a price for national reimbursement, following a positive review by the Haute Autorité de santé (HAS) in December 2024 and initial access for nearly 10,000 patients through an earl...
France Secures Continued Wegovy Access Pending Price Negotiation
Novo Nordisk will continue providing free Wegovy to 3,000 French patients until at least December 2025 while negotiating a price for national reimbursement, following a positive review by the Haute Autorité de santé (HAS) in December 2024 and initial access for nearly 10,000 patients through an earl...
Progress
32% Bias Score
CMS Drug Price Controls Under IRA Threaten Pharmaceutical Innovation
CMS announced price negotiations for 15 drugs under the IRA, imposing penalties up to 95% of U.S. sales for non-compliance; this discourages R&D, potentially resulting in fewer new drugs and harming patients, with studies projecting a loss of 135 new drugs and $663 billion in R&D spending by 2039.
CMS Drug Price Controls Under IRA Threaten Pharmaceutical Innovation
CMS announced price negotiations for 15 drugs under the IRA, imposing penalties up to 95% of U.S. sales for non-compliance; this discourages R&D, potentially resulting in fewer new drugs and harming patients, with studies projecting a loss of 135 new drugs and $663 billion in R&D spending by 2039.
Progress
60% Bias Score
Medicare Selects 15 More Drugs for Price Negotiation
Medicare selected 15 more top-selling prescription drugs for price negotiations under the Inflation Reduction Act, impacting 5.3 million beneficiaries and $41 billion in spending, with expected savings of $1.5 billion in 2027, but the incoming Trump administration may alter the program.
Medicare Selects 15 More Drugs for Price Negotiation
Medicare selected 15 more top-selling prescription drugs for price negotiations under the Inflation Reduction Act, impacting 5.3 million beneficiaries and $41 billion in spending, with expected savings of $1.5 billion in 2027, but the incoming Trump administration may alter the program.
Progress
48% Bias Score
Showing 49 to 60 of 70 results